BR112016007016A8 - composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica - Google Patents
composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica Download PDFInfo
- Publication number
- BR112016007016A8 BR112016007016A8 BR112016007016A BR112016007016A BR112016007016A8 BR 112016007016 A8 BR112016007016 A8 BR 112016007016A8 BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A8 BR112016007016 A8 BR 112016007016A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- dementia
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 150000003839 salts Chemical class 0.000 title 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
derivados de 4-azaindol que são moduladores do receptor muscarínico de acetilcolina (machr) m1 e que podem ser eficazes para a prevenção ou modificação de doença ou tratamento sintomático de déficits cognitivos associados com distúrbios neurológicos, tais como demência do tipo alzheimer (ad) ou demência com corpos de lewy (dcl) e uma composição farmacêutica compreendendo um derivado de 4-azaindol como um ingrediente ativo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1317363.8A GB201317363D0 (en) | 2013-10-01 | 2013-10-01 | Novel compounds |
PCT/IB2014/001978 WO2015049574A1 (en) | 2013-10-01 | 2014-09-30 | 4-azaindole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016007016A2 BR112016007016A2 (pt) | 2017-08-01 |
BR112016007016A8 true BR112016007016A8 (pt) | 2020-02-27 |
Family
ID=49585123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016007016A BR112016007016A8 (pt) | 2013-10-01 | 2014-09-30 | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica |
Country Status (21)
Country | Link |
---|---|
US (3) | US20150094328A1 (pt) |
EP (2) | EP3052496B1 (pt) |
JP (3) | JP6517790B2 (pt) |
KR (1) | KR102248559B1 (pt) |
CN (1) | CN105873927B (pt) |
AR (1) | AR097866A1 (pt) |
AU (1) | AU2014330880B2 (pt) |
BR (1) | BR112016007016A8 (pt) |
CA (1) | CA2924619C (pt) |
CL (1) | CL2016000726A1 (pt) |
ES (2) | ES2710190T3 (pt) |
GB (1) | GB201317363D0 (pt) |
HK (1) | HK1223090A1 (pt) |
IL (1) | IL244609B (pt) |
MX (1) | MX368956B (pt) |
PE (1) | PE20160839A1 (pt) |
PH (1) | PH12016500529A1 (pt) |
RU (1) | RU2688938C2 (pt) |
SG (1) | SG11201602052YA (pt) |
TW (1) | TW201546070A (pt) |
WO (1) | WO2015049574A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
PT3134386T (pt) | 2014-04-23 | 2020-08-25 | Takeda Pharmaceuticals Co | Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer |
WO2015174534A1 (ja) | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
DK3303331T3 (en) * | 2015-06-08 | 2019-04-23 | Suven Life Sciences Ltd | MUSCARIN M1 RECEPTOR-POSITIVE ALLOSTER MODULATORS |
SI3347349T1 (sl) * | 2015-09-10 | 2019-12-31 | Suven Life Sciences Limited | Derivati fluoroindola kot muskarinski M1 receptor pozitivni alosterni modulatorji |
KR20180110132A (ko) * | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
CA3076757C (en) * | 2017-10-18 | 2022-10-11 | Suven Life Sciences Limited | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators |
AU2018354969B2 (en) * | 2017-10-27 | 2020-09-17 | Suven Life Sciences Limited | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators |
US12065433B2 (en) | 2018-10-24 | 2024-08-20 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
KR102347368B1 (ko) * | 2020-11-03 | 2022-01-07 | (주)케이메디켐 | 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
CN118440041B (zh) * | 2024-07-02 | 2024-09-27 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2003044018A1 (en) | 2001-11-19 | 2003-05-30 | Neurogen Corporation | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides |
GB0222743D0 (en) | 2002-10-01 | 2002-11-06 | Celltech R&D Ltd | Chemical compounds |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
JP2006522746A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 置換されたアミドの薬学的使用 |
EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
JP2010511632A (ja) | 2006-11-30 | 2010-04-15 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法 |
CA2691512A1 (en) | 2007-08-10 | 2009-02-19 | H. Lundbeck A/S | Heteroaryl amide analogues |
ATE541845T1 (de) | 2007-08-29 | 2012-02-15 | Schering Corp | 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen |
EP2244577B1 (en) * | 2008-01-25 | 2012-10-31 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
MX2010007661A (es) | 2008-01-31 | 2010-08-03 | Sanofi Aventis | Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos. |
US20110098483A1 (en) | 2008-03-27 | 2011-04-28 | University Of Southern California | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof |
WO2009121623A2 (en) | 2008-04-04 | 2009-10-08 | Summit Corporation Plc | Compounds for treating muscular dystrophy |
US8012992B2 (en) | 2008-06-30 | 2011-09-06 | Allergan, Inc. | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
AU2009283195A1 (en) | 2008-08-18 | 2010-02-25 | Yale University | MIF modulators |
WO2010033980A2 (en) | 2008-09-22 | 2010-03-25 | Isis Innovation Ltd. | 4-azaindole bisphosphonates |
MY162502A (en) | 2008-11-20 | 2017-06-15 | Merck Sharp & Dohme | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
WO2010063634A1 (en) | 2008-12-05 | 2010-06-10 | F. Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
CN102325752B (zh) | 2008-12-19 | 2015-02-04 | 百时美施贵宝公司 | 咔唑和咔啉激酶抑制剂 |
EP2398324B1 (en) | 2009-02-23 | 2014-09-03 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
US8293744B2 (en) | 2009-04-20 | 2012-10-23 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators |
JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
US8816085B2 (en) * | 2009-08-26 | 2014-08-26 | Takeda Gmbh | Methylpyrrolopyridinecarboxamides |
AU2010286683B9 (en) | 2009-08-31 | 2014-09-04 | Merck Sharp & Dohme Llc | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
EP2512245B1 (en) | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
NZ600674A (en) * | 2009-12-17 | 2013-05-31 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
US8383638B2 (en) | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
JP2013515725A (ja) | 2009-12-23 | 2013-05-09 | サノフイ | [4[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−(1h−ピロロ−ピリジン−イル)−メタノン類及びその合成 |
US8883850B2 (en) | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
WO2011159553A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
EP2582676B1 (en) | 2010-06-15 | 2016-12-14 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
EP2624697B1 (en) | 2010-10-04 | 2015-11-25 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
EP2709451B1 (en) | 2011-05-17 | 2015-12-30 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
EP2709621B1 (en) | 2011-05-17 | 2016-11-02 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
EP2709624B1 (en) | 2011-05-17 | 2016-04-27 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
AU2012328476B2 (en) | 2011-10-28 | 2017-03-30 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
WO2013091773A1 (en) | 2011-12-22 | 2013-06-27 | Merck Patent Gmbh | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
US9012445B2 (en) * | 2012-01-12 | 2015-04-21 | Vanderbilt University | Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors |
EA028611B1 (ru) * | 2013-07-17 | 2017-12-29 | Глоубал Элаенс Фор Тб Драг Дивелопмент | Азаиндольные соединения, их получение и способы их применения |
TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
EP3049391B1 (en) * | 2013-09-27 | 2018-12-26 | F.Hoffmann-La Roche Ag | Indole and indazole derivatives |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
-
2013
- 2013-10-01 GB GBGB1317363.8A patent/GB201317363D0/en not_active Ceased
-
2014
- 2014-09-30 PE PE2016000374A patent/PE20160839A1/es not_active Application Discontinuation
- 2014-09-30 MX MX2016004014A patent/MX368956B/es active IP Right Grant
- 2014-09-30 SG SG11201602052YA patent/SG11201602052YA/en unknown
- 2014-09-30 ES ES14799529T patent/ES2710190T3/es active Active
- 2014-09-30 EP EP14799529.4A patent/EP3052496B1/en active Active
- 2014-09-30 KR KR1020167011471A patent/KR102248559B1/ko active IP Right Grant
- 2014-09-30 RU RU2016116775A patent/RU2688938C2/ru active
- 2014-09-30 AU AU2014330880A patent/AU2014330880B2/en not_active Ceased
- 2014-09-30 US US14/501,355 patent/US20150094328A1/en not_active Abandoned
- 2014-09-30 CN CN201480062539.8A patent/CN105873927B/zh not_active Expired - Fee Related
- 2014-09-30 CA CA2924619A patent/CA2924619C/en not_active Expired - Fee Related
- 2014-09-30 BR BR112016007016A patent/BR112016007016A8/pt active Search and Examination
- 2014-09-30 WO PCT/IB2014/001978 patent/WO2015049574A1/en active Application Filing
- 2014-09-30 ES ES18204685T patent/ES2807221T3/es active Active
- 2014-09-30 US US15/025,996 patent/US9926312B2/en active Active
- 2014-09-30 JP JP2016519874A patent/JP6517790B2/ja not_active Expired - Fee Related
- 2014-09-30 EP EP18204685.4A patent/EP3489237B1/en active Active
- 2014-10-01 TW TW103134194A patent/TW201546070A/zh unknown
- 2014-10-01 AR ARP140103638A patent/AR097866A1/es unknown
-
2016
- 2016-03-15 IL IL244609A patent/IL244609B/en active IP Right Grant
- 2016-03-17 PH PH12016500529A patent/PH12016500529A1/en unknown
- 2016-03-29 CL CL2016000726A patent/CL2016000726A1/es unknown
- 2016-09-23 HK HK16111182.7A patent/HK1223090A1/zh unknown
-
2018
- 2018-01-19 US US15/875,069 patent/US10072005B2/en active Active
-
2019
- 2019-03-01 JP JP2019037299A patent/JP2019112433A/ja active Pending
-
2020
- 2020-05-08 JP JP2020082404A patent/JP6899944B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016007016A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
CL2012001955A1 (es) | Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras. | |
CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
ECSP16090152A (es) | Compuesto heterocíclico que contiene nitrógeno | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
PH12018501731A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
BR112018001469A2 (pt) | composto, composição farmacêutica e uso de um composto | |
UY33277A (es) | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
CL2008002876A1 (es) | Compuestos derivados de heterociclo sustituidos, moduladores de gamma-secretasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades neurodegenerativas como alzheimer o sindrome de down. | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
CR20180368A (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
CL2008001559A1 (es) | Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica. | |
WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |